2021 SEP 09 (NewsRx) -- By a
Financial support for this research came from
Our news journalists obtained a quote from the research from
According to the news editors, the research concluded: “HDHPs do not reduce continuity of buprenorphine treatment among commercially insured enrollees with OUD but may increase financial burden for this population.”
This research has been peer-reviewed.
For more information on this research see: Impact of High Deductible Health Plans On Continuous Buprenorphine Treatment for Opioid Use Disorder.
The news correspondents report that additional information may be obtained from
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s11606-021-07094-9. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)